TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02256670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Application
Description: Two-way text messaging application addressing adherence with adjuvant endocrine therapy
Study: NCT00238030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thryoxine
Description: 2 mcg/kg iv or 2 mcg/kg po at time of enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv thryoxine
Description: thyroxine 2 mcg/kg iv
Study: NCT02860481

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample for FSHR analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample for FSHR analysis
Study: NCT01871779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treadmill Exercise
Description: Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent treadmill & resistance training
Description: Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
Study: NCT00238030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv thryoxine
Description: thyroxine 2 mcg/kg iv
Study: NCT01037855

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study
Study: NCT01592903

Intervention type: GENETIC
Intervention: Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.
Description: * Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality.
Study: NCT04088201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose measurements
Description: We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
Study: NCT04340310

Intervention type: DIAGNOSTIC_TEST
Intervention: Home respiratory polygraphy
Description: Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission

Intervention type: DIAGNOSTIC_TEST
Intervention: Home respiratory polygraphy
Description: Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
Study: NCT05961852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: Angioplasty with cutting and drug-coated balloon
Study: NCT03791164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Pain Toolkit
Description: the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the Back Book
Description: The Back Book is a patient information leaflet that offers information and advice about back pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Back Book
Description: The Back Book is a patient information leaflet that offers information and advice about back pain
Study: NCT02138045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide treatment
Description: Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Study: NCT05308550

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: rapid RT-LAMP test to detect SARS-COV-2 RNA
Description: rapid RT-LAMP test to detect SARS-COV-2 RNA
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
Study: NCT03190551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular approach
Description: Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular approach
Description: costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study: NCT01518855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine (Norvasc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diovan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan
Study: NCT03110341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin
Description: rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
Study: NCT03502486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: 20 minutes of cycle ergometry at 50-60% of heart rate max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intense exercise
Description: 20 minutes of cycle ergometry at 70-80% of heart rate max

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading
Description: 20 minutes of seated reading
Study: NCT01111123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)
Description: Steroid on weekends only group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Description: Placebo on weekends only group
Study: NCT02259179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Study: NCT00844857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Fluoxetine Combination (OFC)
Description: OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once daily in the evening for 8 weeks.
Study: NCT00570674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Study: NCT03151980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamam treated skin and sun exposure
Description: Hamam is a skin treatment (soaping and scrubbing).

Intervention type: OTHER
Group type: OTHER
Intervention: Untreated skin and sun exposure
Description: Skin that will not receive Hamam.
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
Study: NCT03160989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercises
Description: The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
Study: NCT00908492

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Skill Building
Description: The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
Study: NCT01247207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study: NCT02979639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
Study: NCT04333420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + BSC
Description: Phase II study part: IFX-1 + BSC

Intervention type: DRUG
Group type: OTHER
Intervention: BSC
Description: Phase II study part: BSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + SOC
Description: Phase III study part: IFX-1 + SOC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: Phase III study part: Placebo + SOC
Study: NCT03523312

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated ablative IMRT (HFA-IMRT)
Description: total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
Study: NCT02063230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 50mg
Description: HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 50mg
Description: HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 50mg
Description: HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 25mg
Description: Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
Study: NCT00685945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control (bradykinin)
Description: Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA + bradykinin
Description: Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide + L-NMMA + bradykinin
Description: Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Study: NCT01366235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate 1000 mg
Description: 1000 mg, 1day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate 1000 mg
Description: 1000 mg, 1day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate 1000 mg
Description: 1000 mg, 1day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate 1000 mg
Description: 1000 mg, 1day
Study: NCT02578381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Pressure Wire
Description: St Jude Medical Pressure Wire
Study: NCT00685945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil + L-NMMA + bradykinin
Description: Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Study: NCT02578381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Pressure Wire
Description: St Jude Medical Pressure Wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of Boston Scientific pressure wire
Study: NCT03391609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
Study: NCT01757834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWUS Elastography
Study: NCT02489786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.25 mg of digoxin daily except friday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.25 mg of digoxin daily except thursday and friday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.125 mg of digoxin daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digoxin dose is calculated using Jusko-Koup method and given daily
Study: NCT03340480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1402
Description: Oral
Study: NCT02629874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
Study: NCT00799292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
Study: NCT00939484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT03122561

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at morning
Description: Single dose oral paracetamol will be administered at 8.00 am

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at midday
Description: Single dose oral paracetamol will be administered at 2.00 pm

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at night
Description: Single dose oral paracetamol will be administered at 8.00 pm
Study: NCT02859610

Intervention type: OTHER
Group type: OTHER
Intervention: research on interactions between portal hypertension and microparticles

Intervention type: OTHER
Group type: OTHER
Intervention: research on interactions between portal hypertension and microparticles
Study: NCT02629874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01599208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study: NCT03019146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Study: NCT02578381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of Boston Scientific pressure wire
Study: NCT03019146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOLD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HUG
Study: NCT00181571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate HCl (Concerta)
Description: up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
Study: NCT02218827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate (FML)
Description: a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
Study: NCT00836082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 0.5mg given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 1mg given once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
Study: NCT02578381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Validation of Boston Scientific pressure wire
Study: NCT01726725

Intervention type: DRUG
Intervention: desflurane